Neogenomics (NEO) Research & Development (2011 - 2026)

Neogenomics (NEO) has reported Research & Development for 16 consecutive years, with $9.5 million the latest figure, recorded in Q1 2026.

• Research & Development for Q1 2026 came in at $9.5 million, down 6.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.4 million (up 8.04% YoY), and the FY2025 annual result was $37.1 million, up 18.99% from the prior year.
• Research & Development was $9.5 million for Q1 2026 at Neogenomics, up from $9.2 million in the prior quarter.
• Over five years, Research & Development peaked at $10.2 million in Q1 2025 and troughed at $5.3 million in Q3 2023.
• Average Research & Development over 5 years is $8.0 million, with a median of $7.7 million recorded in 2022.
• Year-over-year, Research & Development soared 214.05% in 2022 and decreased 27.72% in 2023.
• Over 5 years, Research & Development stood at $6.7 million in 2022, then advanced by 6.77% to $7.1 million in 2023, then gained by 11.81% to $8.0 million in 2024, then gained by 15.18% to $9.2 million in 2025, then grew by 3.87% to $9.5 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $9.5 million in Q1 2026, $9.2 million in Q4 2025, and $8.7 million in Q3 2025.